Accumulating evidence has been proven that PP2A as a tumor suppressor could reverse the actions of protein kinases by dephosphorylating PP2A substrates β-catenin, c-Myc, and Bcl-2 from threonine and serine residues of proteins [29, 30]. The gene discussed is MYC; the disease is neoplasm.